Overview
The goal of this study is to assess the overall success of energy delivery during treatment using the ultrasound guided microwave ablation device in patients with locally advanced, unresectable, or metastatic cancer. Secondly, this study aims to explore the procedural/clinical safety of treatment with the device and the antitumor effect following treatment with the device.
Eligibility
Inclusion Criteria:
- Male or female ≥18 years of age
- Willing and able to provide written informed consent
- Histologically confirmed locally advanced, unresectable or metastatic cancer (Stage III or IV)
- At least 1 tumor that is indicated for MWA, and the location of target tumor must be accessible via EUS through the gastric wall (eg, pancreas, liver, etc).
- The tumor(s) must be ≥1 cm in diameter
Exclusion Criteria:
- Participant is a candidate for upfront resection of pancreatic cancer
- Participation in another clinical trial that involves local ablation or any other local therapy that could affect the target organ or lesions treated in this study
- Any condition that, in the opinion of the investigator, may increase the risk to the participant's safety or well-being


